Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR, TSX:TKM) is a leading RNA interference (RNAi) therapeutics company. With more than 14 years of industry experience, Tekmira has established itself as a global leader in the RNAi field. Tekmira has a diverse pipeline of product candidates in development to treat serious human diseases such as cancer and viral infections like Hepatitis B and Ebola. The company is advancing the development of novel drugs in areas where there is a significant unmet medical need and commercial opportunity. Tekmira also licenses its leading LNP delivery technology to partners around the world.
May 8, 2014
Tekmira's 2014 AGM / Proxy Materials
Apr 1, 2014 at 10:25 AM
6th International Symposium on Filoviruses